Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Agenda
3. "Severe asthma" first definition
4. "Difficult asthma" ERS taskforce definition
5. "Refractory asthma" ATS criteria
6. Revised GINA definition of severe asthma
7. Heterogeneous reasons for severe asthma
8. Reasons for asthma symptoms variety
9. "High dose" therapy
10. Definition summary
11. Treatments for severe asthma?
12. Inflammation type
13. Sinonasal polyposis
14. Effect of CRS treatment on asthma
15. Inflammation in distal airways in severe asthma
16. Extra-fine ICS effect on large and small airways
17. Extra-fine ICS effect on asthma exacerbations
18. Intense and medical resistant inflammation
19. Consistency of sputum eosinophilia over time
20. Allergic vs. intrinsic asthma
21. Mechanism of action of anti IgE
22. Effect of anti IgE on severe asthma exacerbations
23. "Intrinsic" asthma
24. Systemic steroids in 'refractory' eosinophilia
25. Anti IL-5 effect
26. Treatment with oral steroids and anti-IL-5
27. No eosinophilic inflammation
28. Clarithromycin in neutrophilic asthma
29. Macrolides in chronic stable asthma
30. Asthma and obesity
31. Asthma mechanism in obese patients
32. Weight reduction improves asthma
33. Effect of bariatric surgery on asthma severity
34. Down-titrating oral corticosteroids
35. Obese patients asthma summary
36. Eosinophilic inflammation summary
37. No eosinophilic inflammation summary
38. Implications for the future
39. "Electronic nose"
40. U-BIOPRED

Topics Covered

• Difficult asthma and severe refractory asthma
• Heterogeneous reasons for severe asthma
• "High dose" therapy
• Treatments for severe asthma
• Eosinophilic vs. non eosinophilic inflammation
• Effect of CRS treatment on asthma
• Mechanism of action of anti IgE
• Effect of anti IgE on severe asthma exacerbations
• Effect of anti IL-5 (mepolizumab) on spontaneous asthma exacerbations
• Clarithromycin in neutrophilic asthma
• Macrolides in chronic stable asthma
• Mechanisms of asthma severity in obese patients
• Implications for the future

Links

Series:

• Advances in Asthma

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on December 29, 2011

Financial Disclosures

• Prof. Elisabeth Bel, Grant/Research Support (Principal Investigator): unrestricted grant for department from GSK (60,000 EURO), Novartis (16,000 EURO)